| scholarly article | Q13442814 |
| P2093 | author name string | Tao Li | |
| Miao Ding | |||
| Yuhua Li | |||
| Maohua Miao | |||
| Biaoyang Lin | |||
| Fen Yang | |||
| Hongjie Pan | |||
| Jinfa Gu | |||
| Runsheng Li | |||
| Tianqi Li | |||
| Xiaoyu Zhou | |||
| Xin Yuan Liu | |||
| Yuanyuan Liu | |||
| P2860 | cites work | Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter | Q40821528 |
| Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells | Q40848071 | ||
| A new human prostate carcinoma cell line, 22Rv1. | Q40933318 | ||
| miR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer | Q45877197 | ||
| Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells | Q47875189 | ||
| Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. | Q53347619 | ||
| Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. | Q53362101 | ||
| Androgen receptor outwits prostate cancer drugs. | Q53907010 | ||
| NDRG3 is an androgen regulated and prostate enriched gene that promotes in vitro and in vivo prostate cancer cell growth. | Q54509491 | ||
| NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. | Q54707681 | ||
| Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells | Q71674458 | ||
| Effects of 5 alpha-reductase inhibitors on intraprostatic androgens in the rat | Q71935967 | ||
| Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment | Q74544937 | ||
| Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy | Q77651935 | ||
| Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy | Q79920255 | ||
| CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers | Q82208584 | ||
| Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium | Q83177003 | ||
| Identification of novel AR-targeted microRNAs mediating androgen signalling through critical pathways to regulate cell viability in prostate cancer | Q21133676 | ||
| The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44 | Q24617130 | ||
| Cancer statistics, 2012 | Q27860574 | ||
| Molecular determinants of resistance to antiandrogen therapy | Q28236889 | ||
| A microRNA component of the p53 tumour suppressor network | Q28305330 | ||
| In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147 | Q28482047 | ||
| The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. | Q33391782 | ||
| Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor | Q33492327 | ||
| Microrna profiling analysis of differences between the melanoma of young adults and older adults | Q33793054 | ||
| Differential regulation of microRNA stability | Q33799078 | ||
| Lineage relationship of prostate cancer cell types based on gene expression | Q33909346 | ||
| Molecular genetics of prostate cancer: new prospects for old challenges | Q34127462 | ||
| Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells | Q34166215 | ||
| Molecular characterization of human prostate carcinoma cell lines | Q34266176 | ||
| Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities | Q34386388 | ||
| Genomic loss of tumor suppressor miRNA-204 promotes cancer cell migration and invasion by activating AKT/mTOR/Rac1 signaling and actin reorganization | Q34533814 | ||
| Mechanisms and functional consequences of PDEF protein expression loss during prostate cancer progression. | Q35082366 | ||
| Unusual subtypes of prostate cancer | Q35672159 | ||
| PC3 is a cell line characteristic of prostatic small cell carcinoma. | Q36185201 | ||
| Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway | Q36206304 | ||
| Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness | Q36383057 | ||
| Neuroendocrine differentiation in prostate cancer: from lab to bedside | Q37007889 | ||
| Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails | Q37741773 | ||
| A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth | Q38299437 | ||
| Androgen-regulated processing of the oncomir miR-27a, which targets Prohibitin in prostate cancer. | Q38326097 | ||
| Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer | Q38422951 | ||
| Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression | Q39227406 | ||
| Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells | Q39258781 | ||
| Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets | Q39385550 | ||
| Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1. | Q39576706 | ||
| miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth | Q39802027 | ||
| An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation | Q39930107 | ||
| Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells | Q39932777 | ||
| Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease | Q40434477 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| prostate adenocarcinoma | Q18555107 | ||
| adenocarcinoma | Q356033 | ||
| P304 | page(s) | 7686–7700 | |
| P577 | publication date | 2015-04-10 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | A dual yet opposite growth-regulating function of miR-204 and its target XRN1 in prostate adenocarcinoma cells and neuroendocrine-like prostate cancer cells | |
| P478 | volume | 6 |
| Q93081557 | Deficiency in Androgen Receptor Aggravates the Depressive-Like Behaviors in Chronic Mild Stress Model of Depression |
| Q38816103 | Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of Nutraceuticals. |
| Q38518046 | Gene interference strategies as a new tool for the treatment of prostate cancer |
| Q36845833 | Genome-wide identification of target genes for miR-204 and miR-211 identifies their proliferation stimulatory role in breast cancer cells |
| Q49415848 | Long noncoding RNA lncBRM facilitates the proliferation, migration and invasion of ovarian cancer cells via upregulation of Sox4. |
| Q92952317 | MiR-204 suppresses cell proliferation and promotes apoptosis in ovarian granulosa cells via targeting TPT1 in polycystic ovary syndrome |
| Q64953093 | MicroRNA Dysregulation in Cutaneous Squamous Cell Carcinoma. |
| Q100512506 | MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer |
| Q61810938 | MicroRNA-204 inhibits the proliferation, migration and invasion of human lung cancer cells by targeting PCNA-1 and inhibits tumor growth in vivo |
| Q37640599 | MicroRNA-381 inhibits the metastasis of gastric cancer by targeting TMEM16A expression |
| Q91519389 | Molecular pathogenesis of triple-negative breast cancer based on microRNA expression signatures: antitumor miR-204-5p targets AP1S3 |
| Q49505114 | Oncogenic and Tumor-Suppressive Roles of MicroRNAs with Special Reference to Apoptosis: Molecular Mechanisms and Therapeutic Potential. |
| Q49530055 | Oxibendazole inhibits prostate cancer cell growth |
| Q48295305 | RETRACTED: Downregulation of miR-204 expression correlates with poor clinical outcome of glioma patients |
| Q51759890 | SIRT1 and microRNAs: The role in breast, lung and prostate cancers. |
| Q90484008 | The Dual Role of miR-186 in Cancers: Oncomir Battling With Tumor Suppressor miRNA |
| Q38736511 | The UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate cancer cells |
| Q89998761 | The deregulation of miR-17/CCND1 axis during neuroendocrine transdifferentiation of LNCaP prostate cancer cells |
| Q28078421 | The dual regulatory role of miR-204 in cancer |
| Q38859577 | The roles of microRNAs in the progression of castration-resistant prostate cancer |
| Q37577131 | miR-486-3p, miR-139-5p, and miR-21 as Biomarkers for the Detection of Oral Tongue Squamous Cell Carcinoma |
| Q51542696 | miRNA-204 suppresses human non-small cell lung cancer by targeting ATF2. |
Search more.